AstraZeneca (AZN -0.1%) will appoint a new CEO over the next six months and the person should be...

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

AstraZeneca (AZN -0.1%) will appoint a new CEO over the next six months and the person should be aggressive on acquisitions, according to Leerink Swann. Leerink views Forest Labs (FRX +3.5%), a stock it upgraded this morning to Outperform, as the most logical takeover target for AZN, but also feels the company has several other options, including Amylin (AMLN -2.7%) and Salix (SLXP -0.1%).